"He came out in a rash when he was two and was on amoxicillin – he's been down as penicillin allergic ever since." This is one of the most common histories in UK paediatric allergy practice, and it captures a real and widespread problem. Most childhood "penicillin allergy" labels are acquired when a child develops a rash while taking amoxicillin. The rash is attributed to the drug. The label goes into the medical record and persists for decades.
In the majority of cases, the rash was viral – a common consequence of viral infection in young children, particularly if they have viral pharyngitis caused by Epstein-Barr virus (glandular fever, which produces a rash in most children given amoxicillin), or simply a coincidental viral rash during the course of antibiotic treatment. The child was never truly allergic to penicillin. But the label says they are, and it follows them.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers allergy and immunology in children.
Why the Penicillin Allergy Label Problem Matters
The consequences of an inaccurate penicillin allergy label extend well beyond inconvenience. Penicillin and its derivatives (amoxicillin, amoxicillin-clavulanate, flucloxacillin, and others) are first-line antibiotics for many common bacterial infections in children. When a child is labelled as penicillin-allergic, clinicians are required to use second-line antibiotics – often broader-spectrum, less targeted, or with less favourable side-effect profiles.
The antibiotic resistance implications are significant: penicillin-allergic patients receive more broad-spectrum antibiotics (such as fluoroquinolones and clindamycin), which are associated with higher rates of C. difficile infection, higher rates of antibiotic-resistant organisms, and greater selective pressure for resistance in general. The clinical outcome data are also concerning: penicillin-allergic patients have longer hospital stays, higher infection-related mortality, and worse outcomes in surgical settings.
Research by Kimberly Blumenthal at Massachusetts General Hospital and Harvard Medical School has been particularly influential in quantifying these harms and the case for systematic de-labelling.
Types of Penicillin Reactions
True penicillin allergy is an IgE-mediated hypersensitivity reaction – the kind involving mast cell degranulation and potentially anaphylaxis. It presents with urticaria (hives), angioedema (swelling of lips, tongue, or throat), bronchospasm, or anaphylaxis, typically within one hour of taking the drug.
Non-IgE-mediated reactions include delayed maculopapular rashes (appearing days into a course of antibiotics), which may or may not represent true drug allergy; serum sickness-like reactions; and the Stevens-Johnson syndrome / toxic epidermal necrolysis spectrum (rare, severe, and always a contraindication to re-exposure). The viral rash that occurs in children taking amoxicillin for glandular fever is particularly distinctive: it typically appears several days into the course, is widespread and morbilliform (measles-like), and is driven by the interaction between the antibiotic and the Epstein-Barr virus immune response rather than by direct drug allergy.
Who Needs Formal Allergy Assessment
Children who had a reaction that involved features of anaphylaxis (throat swelling, breathing difficulty, collapse) should have formal allergy assessment before any re-exposure is considered. This is a small proportion of those with penicillin allergy labels.
For the majority – children who had a rash (especially a delayed, maculopapular rash) without any systemic features – formal assessment, including skin testing and/or direct oral challenge, is appropriate and safe when conducted in a specialist allergy setting.
The British Society for Allergy and Clinical Immunology (BSACI) and NHS England have both prioritised penicillin allergy de-labelling as a patient safety initiative. NICE has produced guidance supporting this.
Penicillin Allergy Testing and De-labelling
The assessment process for penicillin allergy typically involves a structured history; skin testing (intradermal testing with benzylpenicillin, amoxicillin, and the major/minor determinant mixture where available); and a graded oral challenge with amoxicillin, in which a small dose is given and the patient observed for at least one hour before a full dose is given.
Studies using this approach consistently find that more than 90% of patients with penicillin allergy labels can safely receive penicillin after formal testing. In children, the proportion who de-label is even higher, reflecting the predominance of viral rash reactions in the childhood allergy history.
In England, penicillin allergy assessment is available through specialist allergy clinics. Access varies by region. Primary care-led de-labelling pathways, where a direct oral challenge is offered in a GP surgery for children with low-risk histories (mild delayed rash, no systemic features, more than five years ago), are being developed in some areas to expand access.
What Parents Can Do
If a child carries a penicillin allergy label that was based on a childhood rash without systemic features, it is worth asking for a formal allergy review. This is particularly worth pursuing if the child requires antibiotics regularly (for recurrent infections, or in a child with a chronic condition), or before any planned surgery or procedure where antibiotic prophylaxis might be needed.
The GP can refer to a paediatric allergy clinic. In some areas, the BSACI's online resources include patient information to support the referral conversation.
Key Takeaways
Around 10% of people in the UK have a recorded penicillin allergy, but studies consistently find that more than 90% of them are not truly allergic when formally tested. Most penicillin allergy labels in children are based on rash reactions that occurred during a course of amoxicillin in childhood – frequently a viral rash during a viral infection, not a true drug allergy. Carrying an inaccurate penicillin allergy label has real consequences: children and adults labelled as penicillin-allergic receive broader-spectrum antibiotics when they need treatment, contributing to antibiotic resistance and poorer clinical outcomes. Formal allergy assessment and, where appropriate, direct oral challenge, can de-label the allergy.
